Changes

==General Disease Overview / Description of Cancer Category==

==General Disease Overview / Description of Cancer Category==

Increasingly performed high throughput molecular assays enable deeper and comprehensive understanding of genetic changes in neoplasms, which reflect tumor biology and behavior. Simultaneously, many underlying germline mutations of genes accounting for solid and hematopoietic neoplasms have been progressively identified. These patients usually have an early onset of myeloid malignancies (younger patients), evidence of disease anticipation, multiple cases of myeloid malignancies with multiple generations in a pedigree, and/or life-long defects in platelet number and dysfunction, and/or a personal history of multiple cancers. It is known that familial myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are driven by genomic alterations such as mutations in genes encoding transcription factors (GATA-2, RUNX1, ETV6, and CEBPα) involved in hematopoietic stem and progenitor cell (HSPC) development and differentiation. On this basis, a group of hereditary myeloid disorder (HMD) have been incorporated in the WHO 2016 classification of myeloid neoplasms and acute leukemia.

Increasingly performed high throughput molecular assays enable deeper and comprehensive understanding of genetic changes in neoplasms, which reflect tumor biology and behavior. Simultaneously, many underlying germline mutations of genes accounting for solid and hematopoietic neoplasms have been progressively identified. These patients usually have an early onset of myeloid malignancies (younger patients), evidence of disease anticipation, multiple cases of myeloid malignancies with multiple generations in a pedigree, and/or life-long defects in platelet number and dysfunction, and/or a personal history of multiple cancers. It is known that familial myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are driven by genomic alterations such as mutations in genes encoding transcription factors (''GATA-2'', ''RUNX1'', ''ETV6'', and ''CEBPα'') involved in hematopoietic stem and progenitor cell (HSPC) development and differentiation. On this basis, a group of hereditary myeloid disorder (HMD) have been incorporated in the WHO 2016 classification of myeloid neoplasms and acute leukemia.

There are three categories of genetic predisposed myeloid malignancies:

There are three categories of genetic predisposed myeloid malignancies: